Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Phase 2 Completed 203 enrolled Beni-Suef University

RandomizedParallel-groupOpen-labelTreatment

Summary

A total of 201 participants with chronic HCV GT4 infection were allocated into two groups. One group participants were treated with SOF plus RBV (24 weeks). The second group was treated with SOF plus SMV (12 weeks).

Timeline

Start: 2015-04
Primary completion: 2016-07
Completion: 2016-07

Publications

Results Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty MI, Elbary AAA, Ramadan M. Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4. Ann Gastroenterol. 2019 Jan-Feb;32(1):93-98. doi: 10.20524/aog.2018.0327. Epub 2018 Nov 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ribavirin	Small molecule	1000 mg	Oral
Comparator	Ribavirin	Small molecule	1200 mg	Oral
Comparator	Simeprevir	Small molecule	150 mg	Oral
Comparator	Sofosbuvir	Small molecule	400 mg	Oral

Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Summary

Timeline

Publications

Drugs

Indications